Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop ...

(Reuters) -Superluminal Medicines said on Thursday it had signed a deal with U.S. drugmaker Eli Lilly worth up to $1.3 ...

Viking Therapeutics, Inc. (NASDAQ:VKTX) is pressing ahead in the weight-loss drug race with the launch of its Phase 2 VENTURE ...

The Boston-based AI/ML startup focuses on endocrine and cardiometabolic diseases and will use that expertise to generate new ...

An estimated 2·1 billion adults worldwide are affected by overweight and obesity, a figure projected to reach 3·8 billion by ...

Texas Tech University researchers conducted a comprehensive analysis of available research on the relationship between ...

While it’s been easy to grow a bit desensitized to the seemingly unstoppable sales growth of Novo Nordisk and Eli Lilly’s | ...

Tiny "hidden" proteins lurking in DNA once dismissed as junk may hold the key to the next generation of obesity drugs, ...

The rapid adoption of GLP-1 receptor agonists has fundamentally altered obesity management, with these medications now ...

The studies reviewed were small and heterogeneous and it is unclear which interventions were the most successful.

"Pharmacotherapy can help people living with obesity improve overall health, not just lose weight," says Dr. Sue D. Pedersen, ...

Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's AI-driven ...